Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Loyola University

Status and phase: Completed; Phase 4

Conditions: Renal Insufficiency; Type 2 Diabetes

Treatments: Drug: 0.25 units/kg daily insulin; Drug: 0.5 units/kg daily insulin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00911625

201463

Details and patient eligibility

About

It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisine based on weight with reduction for decreased estimated GFR by MDRD as follows: < 30 ml/min/1.73m2 or on dialysis reduce dose by 50% from weight based calculation.

Full description

This study will enroll 180 hospitalized patients with Type 2 diabetes and moderate to end stage renal insufficiency (estimated glomerular filtration rate is < 30 ml/min/1.73m2 or dialysis) in the Chicagoland area. Participants will be randomized into 1 of 2 protocols after hospital admission. Blood glucose levels will be obtained before meals, at bedtime and whenever necessary for any signs or symptoms of hypoglycemia. The primary endpoint will be the percentage of blood glucose levels reaching goal of 80-180mg/dl. A secondary endpoint will be the percentage of hypoglycemic events, defined as blood glucose values < 60 mg/dl. In addition the percentage of glucose levels within the goal range of 80-180mg.dl will be further separated into excellent control (80-140mg/dl) and acceptable control (141-180mg/dl).

The 2 study groups will be:

1. Glargine & glulisine. The total daily insulin dose will be 0.6 units/kg. Half of this will be given as glargine once daily. The other half will be given as glulisine, divided equally between breakfast, lunch, and dinner with correction factor dosing as needed for elevated premeal hyperglycemia.
2. Glargine & glulisine The calculation for the total daily insulin dose will be 0.3 units/kg. Half of this will be given as glargine in the morning. The other half will be given as glulisine, divided equally between breakfast, lunch, and dinner, with correction factor dosing as needed for elevated premeal hyperglycemia.

All oral agents will be discontinued on admission.

Enrollment: 114 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 Diabetes Mellitus of mor than 1year
• GFR less than 30 ml/min/1.73m2 or dialysis
• Age greater than 18years
• Entry blood glucose (fasting or random) greater than 180mg%

Exclusion criteria

• Type 1 Diabetes Mellitus
• New onset hyperglycemia
• Pregnant
• Solid organ transplant within 1 year
• Steroids prednisone greater than 7.5mg/day or equivalent
• Hospital LOS predicted less than 2 days
• Severe liver disease
• Known hypopituitarism or adrenal insufficiency
• Patients in the ICU
• Patients with hypoglycemic unawareness
• Outpatient insulin dose less than 0.6 units/kg

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

114 participants in 2 patient groups

0.5 units/kg

Active Comparator group

Description:

Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.

Treatment:

Drug: 0.5 units/kg daily insulin

0.25 units/kg

Experimental group

Description:

Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.

Treatment:

Drug: 0.25 units/kg daily insulin